🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Fujian Provincial Hospital clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Fujian Provincial Hospital as lead sponsor. Synced 26 Sep 2026
20Current trials
14Recruiting now
5Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Fujian Provincial Hospital is the lead sponsor of 20 current clinical trials in our China register. 14 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Anlotinib, Dexmedetomidine and Esketamine hydrochloride. The most-studied condition is Hepatocellular Carcinoma.

ClinicalTrials.gov trials by status

  • Recruiting1470%
  • Not yet open420%
  • By invitation210%

Trials by phase

  • Observational945%
  • Not applicable630%
  • Phase 4420%
  • Phase 1/215%
01

Clinical trials sponsored by Fujian Provincial Hospital

20 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
AI-assisted Endoscopic Ultrasound Grading of Early Esophageal Cancer Invasion Depth: A Multicenter, Prospective, Randomized Cohort Study
NCT07251114 · ClinicalTrials.gov ↗ · Esophageal Cancer Stage, Early Esophageal Cancer
Not applicable Recruiting 2025-11 China
Cohort Study in Fujian Province
NCT06102187 · ClinicalTrials.gov ↗ · Chronic Disease
Observational Recruiting 2017-01 China
The Effects of Tai Chi on Metabolic Dysfunction-associated Fatty Liver Disease in Middle-Aged and Older Adults
NCT06717828 · ClinicalTrials.gov ↗ · Non-Alcoholic Fatty Liver Disease
Not applicable Recruiting 2024-11 China
Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
NCT06602011 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
Observational Recruiting 2024-09 China
Personalized Interventions Via Health Portraits in Mild Behavioral Impairment
NCT06416514 · ClinicalTrials.gov ↗ · Neurocognitive Disorders
Not applicable Recruiting 2024-06 China
Dexmedetomidine Reduces Sevoflurane MAC-BAR During Pneumoperitoneum
NCT06575179 · ClinicalTrials.gov ↗ · Laparoscopic Cholecystectomy
Phase 4 Recruiting 2024-09 China
Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
NCT06561399 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Non-resectable
Observational Recruiting 2024-08 China
Effects of Different Continuous Renal Replacement Therapy Patterns on Ionized Calcium in Patients With Citrate Anticoagulants Using Calcium-containing Replacement Solutions
NCT06021080 · ClinicalTrials.gov ↗ · Renal Injury, Regional Citrate Anticoagulation, Continuous Renal Replacement Therapy
Observational Recruiting 2023-10 China
Neoadjuvant Triple Therapy for Resectable HCC
NCT06569498 · ClinicalTrials.gov ↗ · Resectable Hepatocellular Carcinoma
Observational Recruiting 2024-09 China
mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
NCT06761027 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
Phase 1/2 Recruiting 2024-12 China
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
NCT06643208 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma
Observational Recruiting 2024-07 China
Impact of the Digital Multi-domain Cognitive Intervention in High-risk Populations for Dementia
NCT06442943 · ClinicalTrials.gov ↗ · Cognitive Dysfunction
Not applicable Recruiting 2024-06 China
Deeper Intubation Make Effects on Cervical Esophageal ESD
NCT06420258 · ClinicalTrials.gov ↗ · Carcinoma in Situ of Cervical Part of Esophagus
Phase 4 Recruiting 2022-10 China
Effects of Esketamine on Postoperative Behavioral Changes in Children Undergoing Tonsillectomy and/or Adenoidectomy
NCT06579937 · ClinicalTrials.gov ↗ · Behavior Problem
Phase 4 Recruiting 2024-09 China
Dose-Response Interaction of Metoprolol and Sufentanil for Attenuating Hemodynamic Responses in Tracheal Intubation
NCT07597564 · ClinicalTrials.gov ↗ · General Anesthesia; Tracheal Intubation
Phase 4 Not yet open 2026-06 China
Prospective Lifespan Cohort of Myocardial Infarction
NCT07471763 · ClinicalTrials.gov ↗ · Acute Myocardial Infarction (AMI), Stable Angina, Unstable Angina
Observational Not yet open 2026-04 China
Electroacupuncture for Preventing Postoperative Delirium in Older Adults Undergoing Total Knee Arthroplasty
NCT06564506 · ClinicalTrials.gov ↗ · Postoperative Delirium
Not applicable Not yet open 2025-11 China
Moderate-Intensity Aerobic Calisthenics for Rural Elderly With Motoric Cognitive Risk Syndrome
NCT07658469 · ClinicalTrials.gov ↗ · Cognition Disorders, Aged
Not applicable Not yet open 2026-07 China
The Efficacy of Sequential RT After Triple Therapy for uHCC
NCT07052448 · Hepatocellular Carcinoma
Observational By invitation 2020-11 China
Survival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic Therapy
NCT07290764 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
Observational By invitation 2025-12 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Fujian Provincial Hospital trials

5 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Fujian Provincial Hospital trials

25 conditions
Hepatocellular Carcinoma3Esophageal Cancer Stage1Early Esophageal Cancer1Chronic Disease1Non-Alcoholic Fatty Liver Disease1Neurocognitive Disorders1Laparoscopic Cholecystectomy1Hepatocellular Carcinoma Non-resectable1General Anesthesia; Tracheal Intubation1Renal Injury1Regional Citrate Anticoagulation1Continuous Renal Replacement Therapy1Acute Myocardial Infarction (AMI)1Stable Angina1Unstable Angina1Resectable Hepatocellular Carcinoma1Locally Advanced Pancreatic Cancer1Metastatic Pancreatic Cancer1Postoperative Delirium1Cognition Disorders1Aged1Intrahepatic Cholangiocarcinoma1Cognitive Dysfunction1Carcinoma in Situ of Cervical Part of Esophagus1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China2014

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Hepatocellular Carcinoma

SponsorTrials
Sun Yat-sen University23
The First Affiliated Hospital with Nanjing Medical University4
Chinese PLA General Hospital4
Akeso3
Shanghai Junshi Bioscience3
Zhongda Hospital3
Guangxi Medical University3
Replimune2
HistoSonics2
Teclison2

Sponsors with the most current trials registered for this condition.

06

Questions about Fujian Provincial Hospital trials

How many clinical trials does Fujian Provincial Hospital sponsor?

Fujian Provincial Hospital is the lead sponsor of 20 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Fujian Provincial Hospital trials recruiting?

Yes. 14 of its 20 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Fujian Provincial Hospital testing?

Its current trials name 5 drugs and biologicals as interventions. The most frequent are Anlotinib (1), Dexmedetomidine (1), Esketamine hydrochloride (1), Sintilimab (1) and Sufentanil (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.